Cerecor Inc. to Present at the Roth Conference on March 16th
BALTIMORE-- Cerecor Inc. (NASDAQ: CERC), a clinical-stage biopharmaceutical company developing treatments to make a difference in the lives of patients with neurological and psychiatric disorders, today announced that it has been invited to present at the 28th Annual ROTH Conference to be held on March 13-16, 2016 at The Ritz Carlton in Orange County, California.
Dr. Uli Hacksell, CEO, President, and Chairman of Cerecor, is scheduled to present on Wednesday, March 16th at 12:30 p.m. PST, with one-on-one meetings held throughout the day.
For additional information or to schedule a one-on-one meeting with Cerecor management, please contact your ROTH representative.
A live webcast of the Cerecor presentation may be accessed under the “Investors & Media” section of the company’s website at http://www.cerecor.com.
About Cerecor
Cerecor is a biopharmaceutical company with
the goal of becoming a leader in the development of innovative drugs
that make a difference in the lives of patients with neurological and
psychiatric diseases. We are committed to the development of drugs that
improve lives by applying our extensive knowledge and experience in
central nervous system disorders. Cerecor is currently pursuing the
development of two clinical Phase II-stage product candidates: CERC-301:
An oral, NR2B specific, NMDA receptor antagonist targeting the
adjunctive treatment of patients with MDD who are failing to achieve
adequate response, and CERC-501: An oral, potent and selective kappa
opioid receptor (KOR) antagonist targeting the adjunctive treatment of
MDD and substance use disorders. In addition Cerecor is in preclinical
development with CERC-406, a brain penetrant COMT inhibitor with
potential procognitive activity. For more information about the Company
and its products, please visit: www.cerecor.com
or contact Mariam E. Morris, Chief Financial Officer, at (443) 304-8002.
View source version on businesswire.com: http://www.businesswire.com/news/home/20160308005630/en/
MacDougall Biomedical Communications
Doug MacDougall or Joe Rayne,
781-235-3060
ir@cerecor.com
Source: Cerecor Inc.
Released March 8, 2016